Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more

A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/9e91be7c750cf4fb7c843935780a090d86c67d22"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more"></iframe>

STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more

More from Health

STAT+: FDA expands Bayer lung cancer drug approval

STAT+: Cancer medicines remain in short supply across the U.S., survey finds

Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree

STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more

More from Health

STAT+: FDA expands Bayer lung cancer drug approval

STAT+: Cancer medicines remain in short supply across the U.S., survey finds

Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree

STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more